LOGO
LOGO

Breaking News

Applied Industrial Technologies Adjusts FY26 EPS Guidance

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

Applied Industrial Technologies (AIT) adjusted fiscal 2026 EPS guidance to a range of
$10.45 to $10.75, from prior guidance range of $10.10 to $10.85 following first half performance. Updated guidance now assumes sales growth of 5.5% to 7.0%, updated from prior range of up 4.0% to 7.0%, including up 2.5% to 4.0% on an organic basis revised from prior range of up 1.0% to 4.0%.

For the second quarter, the company's bottom line totaled $95.34 million, or $2.51 per share. This compares with $93.29 million, or $2.39 per share, last year. Sales rose 8.4% to $1.163 billion from $1.073 billion last year. Sales increased 2.2% on an organic basis.

Applied Industrial Technologies also announced the acquisition of Thompson Industrial
Supply Inc. Based in Los Angeles, CA, Thompson is a provider of industrial bearings, power transmission, hydraulics, pneumatics, linear motion, and lightweight belting products and related service solutions.

The company also announced that its Board of Directors approved an 11% increase in the quarterly cash dividend to $0.51 per common share, payable on February 27, 2026, to shareholders of record on February 13, 2026.

In pre-market trading on NYSE, Applied Industrial shares are down 0.15 percent to $281.12.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

Latest Updates on COVID-19